A nonradioactive, microsphere-based, no-wash assay for the measurement of p38α mitogen-activated protein (MAP) kinase activity was established. In this assay, a glutathione-S-transferase activating transcription factor 2 (amino acids 19-96) fusion protein (GST-ATF-2) was used as substrate for p38α MAP kinase. The assay involves immobilization of GST-ATF-2 on glutathione-microspheres (GSH-microspheres), addition of test solution containing p38α MAP kinase and test compounds, and measurement of the respective substrate phosphorylation with the aid of a bi-phospho-specific antibody. The optimization of test conditions is described in this article. With an optimized standard protocol, p38α MAP kinase inhibitors were investigated and IC 50 values were compared to those derived using known assays. This assay might be useful in testing drug candidates. (Journal of Biomolecular Screening 2006:528-536) 
INTRODUCTION
T HE P38α MITOGEN-ACTIVATED PROTEIN (MAP) kinase signaltransduction pathway is activated by extracellular stimuli such as cell stress and proinflammatory cytokines (in vitro and in vivo). 1, 2 The consequence of its activation is the autoinduction of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), that are important in both the induction and progression of many inflammatory diseases, such as arthritis (RA) and inflammatory bowel disease (IBD). 3, 4 The p38α MAP kinase is therefore a valid target for novel anti-inflammatory drugs. 5 Despite extensive research on small molecules, 4, 6 no candidate inhibitor has progressed to the later stages of clinical development. Therefore, there is a continuous need for fast and reliable in vitro screening assays with which to evaluate potential drug candidates.
Various p38α MAP kinase assays currently exist. Many of them are performed in solution, using [ 32 P]ATP as the cosubstrate. Such assays can be difficult and laborious as, among other things, [ 32 P] is a high-energy β−emitter that requires careful handling and generates radioactive waste. Such assays are therefore not suitable for mass screening. There are also a few nonradioactive, enzyme-linked immunosorbent assay (ELISA)-format assays described in the literature. 7, 8 Both use activating transcription factor 2 (ATF-2) as a substrate for p38α MAP kinase. One microsphere-based kinase assay is already commercially available (Upstate), but detailed assessments of its performance have yet to be published.
For assaying with a Luminex 100 analyzer, so-called microspheres are needed. Microspheres are color-coded tiny beads. One hundred different beads are available, allowing theoretically the assaying of 100 analytes in parallel. Each bead set can be coated with a reagent specific to a particular bioassay (e.g., glutathione [GSH]), allowing the capture and detection of specific analytes from a sample. For the detection and the subsequent measuring with the Luminex 100 analyzer, antibodies labeled with a fluorescent substance (e.g., R-phycoerythrine) are needed. Within the Luminex 100 analyzer, lasers excite the internal dyes that identify each microsphere particle and also any reporter dye captured during the assay. In our test, 100 readings are made on the bead set, further validating the results. 9 The small surface area and 3-dimensional agitation of microspheres during an assay allows nearly solution-phase kinetics, in contrast to ELISA-based assays, which are limited by solid-phase kinetics. 9 Multiplex technology allows the user to demonstrate the inhibitory potential of 1 test compound on several different enzymes in just 1 assay, as long as the substrate specificity of the kinases used is high enough that phosphorylation of substrates by 2 or more kinases can be excluded.
Another advantage of multiplex technology is the option of performing no-wash assays. Without plate-washing steps, the handling of the assay is faster and simpler than in a conventional ELISA-based assay. Furthermore, bead-based assays can be run with lower sample volumes than those required by conventional ELISA-based assays. This can help to make testing more cost-effective.
In this study, we present a bead-based, p38α MAP kinase assay.
MATERIALS AND METHODS

Materials
The following reagents were used: assay buffer (Progen, Heidelberg, Germany); GSH microspheres (Progen); polyclonal ATF-2 antibody and polyclonal anti-phospho-ATF-2 (Thr69/71) antibody (Cell Signaling Technology, Beverly, MA); glutathione-S-transferase activating transcription factor 2 fusion protein (GST-ATF-2) (amino acids 19-96) (Upstate Cell Signaling Solutions, Lake Placid, NY); donkey-anti-rabbit R-phycoerythrin-conjugated F(ab´) 2 fragment antibody (Jackson Immunoresearch Laboratories, West Grove, PA); activated p38α MAP kinase (synthesized by and bought from Prof. Dr. J. Schultz, Institute of Pharmaceutical Chemistry, University of Tübingen); Nunc-Immuno™ 96-well microplates and F96 Maxisorp (VWR-International GmbH, Bruchsal, Germany); SB 203580 (synthesized in our laboratory 11 ); bovine serum albumin (BSA) fraction V, dithiothreitol (DTT), and 1.5-mL safe-lock tubes (Eppendorf AG, Hamburg, Germany); sodium orthovanadate and SB202190 (Sigma-Aldrich Chemie, Steinheim, Germany); adenosine-5´-triphosphate disodium salt hydrate, β-glycerophosphate, MgCl 2 × 6 H 2 O ultra for molecular biology, sodium azide, and Tris(hydroxymethyl)aminomethane hydrochloride (Fluka, Buchs, Switzerland); DMSO, HCl, NaOH, SB239063, and Tris(hydroxymethyl)aminomethane (Merck, Darmstadt, Germany); Dulbecco's phosphate-buffered saline without Ca, Mg, and sodium hydrogen carbonate (DPBS) and Dulbecco's phosphate-buffered saline powder without Ca and Mg (Gibco, Invitrogen, Basel, Switzerland); and Tween-20 (Bio-Rad Laboratories, Hercules, CA).
Assay protocol
The concentrations of the enzyme substrates and antibodies (data not shown) were optimized by serial dilution or apparent K m value determination. All incubations were done in a microplate incubator (Titramax 1000 with incubator 1000, Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) at 37 °C.
Coupling of GSH beads with GST-ATF-2
For the coupling of the GSH beads with GST-ATF-2, the protein stock solution containing 5 mg/mL GST-ATF-2 was diluted in a 1.5-mL safe-lock tube with Tris-buffered saline (TBS, 50 mM Tris-HCl, 150 mM NaCl, pH 7.5) 1:6.25. Equal volumes of GSH bead suspension (2000 beads/µL) and diluted GST-ATF-2 solution were mixed in a 1.5-mL safe-lock tube. After the mixture was incubated for 2 h in the dark, it was centrifuged for 2 min at 13,000 rpm (Kendro Biofuge Fresco, Kendro GmbH, Hanau, Germany). The supernatant was discarded. The beads were washed once with TBS and centrifuged, and the supernatant was removed. This washing procedure was repeated with kinase buffer (KB, 50 mM Tris-HCl [pH 7.5], 10 mM MgCl 2 , 10 mM β-glycerophosphate, 100 µg/mL BSA, 0.1 mM Na 3 VO 4 , 1 mM DTT, and 100 µM adenosine triphosphate [ATP] or 200 µM ATP) as washing solution. The remaining beads were diluted to a final concentration of 2000 beads/5 µL with KB. Beads are freshly coupled before each test.
Detection of bound GST-ATF-2
A 96-well microplate was incubated with 350 µL blocking buffer (TBS containing 0.25% BSA, 0.05% Tween-20, and 0.02% NaN 3 ) per well for 1 h at 37 °C. The plate was then washed 3 times with water. Then, 5 µL of bead suspension was added to each well, and then 20 µL of DPBS and 25 µL of ATF-2 antibody (1:500 in assay buffer, AP) were added. This mixture was incubated for 1 h at 37 °C in the dark, with shaking at 300 rpm. Next, 50 µL of R-phycoerythrin-conjugated donkeyanti-rabbit-antibody for detection (1:80 in AP) was added and incubated for 1 h at 37°C in the dark, with shaking at 300 rpm. Finally, 25 µL DPBS was pipetted into each well. The fluorescence of the bound detection antibody was immediately measured with the Luminex 100 analyzing system (Luminex During the injection of the sample into the cuvette, the microspheres are surrounded by sheath fluid (Progen, Heidelberg, Germany) in a way that ensures a laminar flow between the focused sample stream and the surrounding sheath fluid tunnel. By this process of hydrodynamic focusing, the microspheres are singularized and precisely directed through the focus of the laser-based detection system. For both the classification of the microspheres and the quantitative detection of bound reporter molecules, there are 2 solid-state lasers installed on the optics platform of the analysis system. Both laser beams are aligned to the center of the focused particle stream inside the cuvette. The fluorescence signals that are emitted in a direction perpendicular to the 2 laser beams are directed to the respective detectors via mirrors and filters. 10 APD, avalanche photo diode; PMT, photomultiplier.
Corporation, Austin TX). One hundred beads were measured per well.
p38α α MAP kinase assay
A 96-well microplate was incubated with 350 µL blocking buffer per well for 1 h at 37 °C to block open binding sites. The plate was then washed 3 times with water. Next, 20 µL of test solution (respectively 20 µL of KB for the blank values or 20 µL of test solution without test compound for the stimulation control) and 5 µL of bead suspension of freshly coupled beads were added to the wells and incubated for 30 min at 37°C in the dark, while shaking at 300 rpm. The test solution contained 2.4 µg/mL p38α MAP kinase (1.2 µg/mL) diluted in KB with or without test compound in varying concentrations (10 -4 M to 10 -8 M). Initially, the test substances were dissolved in DMSO to stock solutions of 10 -2 M, and all further dilution steps were carried out in kinase buffer containing p38α MAP kinase. After 25 µL of phospho-ATF-2 (Thr69/71) antibody (1:250 in AP) was added to each well, the plate was incubated for 1 h at 37°C in the dark, with shaking at 300 rpm. Then, 50 µL of R-PE-conjugated donkey-anti-rabbit-antibody for detection (1:80 in AP) was added, and the plate was incubated for 1 h at 37°C in the dark, with shaking at 300 rpm. Next, 25 µL of DPBS was added to each well. The fluorescence of the bound detection antibody was immediately measured with the Luminex 100 analyzing system. One hundred beads were measured per well. To stop the kinase reaction, the AP used for antibody dilution contained SB 203580 at a concentration of 100 µM.
RESULTS
In the assay described in this article, a GST-ATF-2 fusion protein was used as a substrate for the p38α MAP kinase. The assay involves immobilization of GST-ATF-2 on GSH microspheres, addition of a test solution containing p38α MAP kinase and test compounds, and measurement of substrate phosphorylation with the aid of a bi-phospho-specific antibody. The optimization of test conditions such as the GST-ATF-2 concentration, enzyme concentration, ATP concentration, and incubation time is described in the following sections. The optimized parameters are incorporated in the standard protocol described in the Materials and Methods section. With an optimized standard protocol, p38α MAP kinase inhibitors were investigated and the IC 50 values were compared to those derived using known assays.
The choice of the primary antibody and detection antibody
For the detection of GST-ATF-2 coupled to GSH beads, an ATF-2 antibody was used. All the antibodies used are commercially available.
GST-ATF-2 is phosphorylated by the p38α MAP kinase at Thr69 and Thr71 but not at Ser190. 1, 12 Phosphorylation on these 2 threonines causes increased transcriptional activity. 1, 13 The kinetic mechanism of the biphosphorylation is a 2-step distributive mechanism: the p38α MAP kinase dissociates from the ATF-2 after each phosphorylation step. 14 Hence, a phosphoepitope-specific antibody that recognizes only ATF-2 that is phosphorylated on both positions (Thr 69 and Thr 71) was used.
Both primary antibodies recognized their bead-bound target protein efficiently.
The primary antibodies we used were produced by immunizing rabbits with the respective target proteins. A donkeyanti-rabbit-R-PE conjugate antibody was used as the detection antibody.
Neither the phospho-epitope-specific antibody nor the detection antibody recognized unphosphorylated GST-ATF-2 (data not shown).
Optimization of the GST-ATF-2 coupling concentration
The coupling of GSH beads with GST-ATF-2 was investigated at different concentrations of GST-ATF-2. Bound GST-ATF-2 was detected by an ATF-2-specific antibody. As shown in Figure 2 , there is an almost linear range up to 500 µg/mL, and the maximum coupling is at 500 µg/mL. We chose 400 µg/mL GST-ATF-2 as the coupling concentration in the assay protocol.
Is GST-ATF-2 coupled to beads still recognized as substrate by p38α α MAP kinase?
To check whether the enzyme would recognize bound GST-ATF-2 as a substrate, we incubated microspheres coupled with GST-ATF-2 at different concentrations with p38α MAP kinase. GST-ATF-2 coupled to GSH beads is well phosphorylated by p38α MAP kinase (Fig. 3) . This indicates that substrate immobilization on GSH beads does not result in severe conformational 
Determination of the apparent K m value of ATP
To define balanced assay conditions, the apparent K m value for ATP was determined. According to Copeland, 15 the substrate concentration should be set equal to its K m value. If this is not possible, the substrate concentration should be below the K m to maintain sensitivity.
To obtain apparent K m values for the substrate ATP, the kinetic data were fitted by nonlinear regression into the Michaelis-Menten equation using the LSW data analyzing toolbox (MDL Information Systems, San Ramon, CA). We determined an apparent K m value of 104 ± 2.5 µM (Fig. 4) . Thus, the ATP concentration used in the assay was set to 100 µM.
Incubation time and enzyme concentration
As shown in Figure 5 , the phosphorylation rate was linear from 5 to 60 min for all ATF-2 concentrations. As the best compromise for a short incubation time, high signal intensity, and sensitivity within the linear range, the incubation time for p38α MAP kinase was set to 30 min.
The enzyme concentration for the standard testing procedure was set to 2.4 µg/mL. The signal-to-enzyme relationship seems to be almost linear in this range for all 3 GST-ATF-2 concentrations tested.
p38α α MAP kinase inhibition by different inhibitors
To validate the p38α MAP kinase assay, the IC 50 values of several known p38α MAP kinase inhibitors were determined.
These results were compared with published data and with data collected with our recently published nonradioactive, highthroughput screening (HTS) ELISA. 8 GST-ATF-2, ATP, and p38α MAP kinase concentrations remained as described above.
All test compounds were dissolved in DMSO to stock solutions of 10 2 M, and all further dilution steps were carried out in kinase buffer containing p38α MAP kinase. The maximum DMSO concentration in the test solution is 0.1%. DMSO is well tolerated by p38α MAP kinase up to a concentration of 0.5% (Fig. 7) .
First, we tested the pyridinyl imidazole derivatives SB 203580 and SB 202190, as well as the pyrimidinyl imidazole derivative SB 239063. All 3 are known to be specific and potent ATP-competitive 16 p38α MAP kinase inhibitors, with IC 50 values in the nanomolar range. [16] [17] [18] [19] [20] As presented in Table 1 , IC 50 values determined with this test agreed with IC 50 values determined with our ELISA-based assay and with published data.
The assay reproducability was tested for SB 203580 at a concentration of 0.1 µM. The inhibition of p38α MAP kinase by SB 203580 at this concentration was an average of 51.6% ± 3.9%.
Finally, p38α MAP kinase inhibitors synthesized in our laboratory were tested. Among them, the substituted isoxazoles MF 335 and MF 355, 28 the 2,4,5 trisubstituted imidazoles AL 089 and AL 099, 29 FIG. 4. Determination of the apparent K m value for adenosine triphosphate (ATP). The rate of phosphorylation at the maximal ATP concentration was set to 100%. The reactions were done with 2.4 µg/mL p38α mitogen-activated protein (MAP) kinase and 400 µg/mL glutathione-Stransferase activating transcription factor 2 (GST-ATF-2). K m was determined according to Forrer et al. 7 Each data point represents the mean of 4 determinations ± SEM. The rate of phosphorylation at the maximal ATP concentration was set to 100%. The kinetic data were fitted by nonlinear regression into the Michaelis-Menten equation using the LSW data analyzing toolbox (MDL Information Systems) to obtain apparent K m values for the cosubstrate ATP. The determined apparent K m value was 104 ± 2.5 µM. derivatives RU 039, RU 102, RU 139, RU 181, RU 363, and RU 371 30, 31 were tested. All of them are supposed to be ATPcompetitive inhibitors of p38α MAP kinase, as they are structurally very closely related to SB 203580. 16 The IC 50 values determined for these inhibitors corresponded very well with IC 50 values determined with our well-established and recently published ELISA-based assay. 8
Are the tested inhibitors really just ATP competitive or are they also ATF-2 competitive?
To test if the inhibitors used are really just ATP competitive, they were assayed using different GST-ATF-2 coupling concentrations; 160 µg/mL was chosen as it is in the middle of the linear range, 400 µg/mL was chosen as the optimal coupling concentration at the end of the linear range, and 1000 µg/mL was chosen as the coupling concentration as it is well above the linear range (Fig. 2) . ATP and p38α MAP kinase concentrations remained as described above.
As presented in Table 2 , the GST-ATF-2 concentration barely influenced the IC 50 values of all tested inhibitors. They are all exclusively ATP competitive.
Does changing the concentrations of ATP and p38α α MAP kinase influence the IC 50 values of inhibitors?
To examine the influence of changing the ATP and p38α MAP kinase concentrations on IC 50 values, we determined the IC 50 values of various inhibitors using an ATP concentration of 200 µM and 1.2 µg/mL p38α MAP kinase. The IC 50 values were determined using 3 different GST-ATF-2 concentrations, as described in the previous section. The incubation time was still 30 min and was within the linear range (Fig. 8) .
The IC 50 values are presented in Table 3 .
IC 50 values did not change, although a higher ATP and a lower p38α MAP kinase concentration were used. The p38α MAP kinase concentration used is hardly within the linear range (data not shown). 
DISCUSSION
The p38α MAP kinase plays a crucial role in signal transduction in inflammatory diseases such as RA and IBD. To develop effective p38α MAP kinase inhibitors, a fast and reliable in vitro enzyme assay is needed to evaluate the inhibitory properties of candidate compounds. We established a novel, nonradioactive, in vitro screening assay that might be useful in testing drug candidates.
GST-ATF-2 bound to GSH microspheres was efficiently recognized by the specific polyclonal ATF-2 antibody, and p38α MAP kinase phosphorylated GST-ATF-2 coupled to GSH microspheres. For the detection of phosphorylated GST-ATF-2, a polyclonal phospho-ATF-2 (Thr69/71) antibody was used. Preblocked plates were used in all tests to avoid a loss of enzyme due to unspecific binding to the well surface.
The IC 50 values obtained with this optimized assay were well within the range of published data and the IC 50 values determined with our recently published ELISA-format p38α MAP kinase assay. Furthermore, the assay reproducibility for single-concentration screening was tested with SB 203580. At a concentration of 0.1 µM, the inhibition of p38α MAP kinase was an average of 51.6% ± 3.9% (n = 10). According to Zhang et al. 32 a Z′ factor of 0.84 was determined for this assay (n = 7). This statistical parameter is used for the characterization of high-throughput assays. A Z′ factor of 0.84, as determined for our assay, means that this assay is well qualified for HTS.
With regard to intra-and interassay variation, a microspherebased assay should be superior to conventional ELISA. In a microsphere-based assay, 100 beads (out of 2000) per well are measured. In contrast, there is only 1 reading point in a conventional ELISA. The result of a microsphere-based assay is always the median of 100 reading points, so this assay is less sensitive to outliers than an ELISA with just 1 reading point. This is confirmed by our data. The average IC 50 value of SB 203580 is 0.096 µM, tested with optimized conditions. The intra-assay variation was as follows: SEM, 0.014; coefficient of variation, 21.0%; and standard deviation, 0.02. Interassay variation (n = 10) was as follows: SEM, 0.016; coefficient of variation, 54.0%; and standard deviation, 0.052. In contrast, the intra-and interassay variation of our recently published p38α MAP kinase ELISA was worse (intra-assay variation: SEM, 0.053 ± 0.005 0.050 ± 0.008 0.044 5,20 n = 4 n = 3 MF 335 28 0.182 ± 0.050 0.447 ± 0.070 n = 3 n = 3 MF 335 28 0.536 ± 0.118 2.010 ± 0.260 n = 4 n = 3 AL 089 29 0.028 ± 0.001 0.025 ± 0.003 n = 4 n = 3 AL 099 29 0.429 ± 0.012 0.399 ± 0.051 n = 4 n = 3 RU 039 30 0.261 ± 0.010 0.323 ± 0.032 n = 3 n = 3 RU 102 31 0.247 ± 0.014 0.388 ± 0.040 n = 3 n = 3 RU 139 31 2.873 ± 0.105 5.283 ± 0.605 n = 3 n = 3 RU 181 30 0.031 ± 0.002 0.020 ± 0.006 n = 3 n = 3 RU 363 30 0.107 ± 0.041 0.224 ± 0.013 n = 3 n = 3 RU 371 30 0.073 ± 0.028 0.035 ± 0.005 n = 3 n = 6
Assay conditions for the microsphere-based assay: 100 µM adenosine triphosphate (ATP), 2.4 µg/mL p38α mitogen-activated protein (MAP) kinase, and 400 µg/mL glutathione-Stransferase activating transcription factor 2 (GST-ATF-2). Enzyme activities were analyzed in the presence of increasing concentrations of inhibitors. The ATP concentration was set equal to the determined K m value. ELISA, enzyme-linked immunosorbent assay. 0.020; coefficient of variation, 34.1%; and standard deviation, 0.035; interassay variation [n = 12]: SEM, 0.029; coefficient of variation, 117.2%; and standard deviation, 0.10). One advantage we used for establishing this assay was the possibility of performing no-wash assays. Without platewashing steps, we found that the handling of the assay is faster and simpler than in a conventional ELISA-based assay. No washing buffers or plate washers are needed.
Another typical advantage of microsphere-based assays is the simultaneous determination of multiple analytes. The Luminex 100 analyzer provides the possibility of discriminating between 100 different colored beads. Theoretically, up to 100 different substrates can be used in 1 assay. This would allow testing of the inhibitory potential and selectivity of a test compound with 100 kinases at the same time. The limiting factor is the low-substrate specificity of kinases. JNK3, for example, would also phosphorylate GST-ATF-2. Using JNK3 and p38α MAP kinase in 1 assay is impossible, as both phosphorylate the same substrate, and differentiation between JNK3 and p38α MAP kinase inhibitors would be impossible. The selectivity profiles of candidate kinase inhibitors are among their most interesting properties. As simultaneous selectivity testing is still an unmet need, there is continuous interest in developing such assays. However, further work is necessary to identify (possibly artificial) substrates with higher selectivity for various kinases.
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Assay conditions for the microsphere-based assay: 100 µM adenosine triphosphate (ATP), 2.4 µg/mL p38α mitogen-activated protein (MAP) kinase, and 160, 400, and 1000 µg/mL glutathione-S-transferase activating transcription factor 2 (GST-ATF-2). Enzyme activities were analyzed in the presence of increasing concentrations of inhibitors. The ATP concentration was set equal to the determined K m value. 
